KCM
CVAC

Kathmere Capital Management’s CureVac CVAC Stock Holding History

Kathmere Capital Management’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,134
Closed -$60.5K – 535
2025
Q2 		$60.5K Buy
+11,134
New +$44.2K ﹤0.01% 483

Other funds holding CVAC

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BA
Bridgewater Associates Westport, Connecticut $22.4B AUM 34.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kathmere Capital Management's CVAC Position: Q3 2025 in Review

Kathmere Capital Management sold out of CureVac (CVAC) in Q3 2025, closing a stake of 11,134 shares — an estimated $60.5K sold.

Kathmere Capital Management first reported a position in CVAC in Q2 2025 and held it in 1 quarter. The position peaked at $60.5K in Q2 2025. 94 funds tracked by Wall St. Rank hold CVAC as of Q3 2025.

  • Kathmere Capital Management reported no remaining CureVac position as of Q3 2025 after selling out during the quarter.
  • Kathmere Capital Management sold 11,134 CureVac shares in Q3 2025, an estimated $60.5K.
  • Kathmere Capital Management first reported a position in CureVac in Q2 2025 and held it in 1 quarter.
  • Kathmere Capital Management's CureVac position peaked at $60.5K in Q2 2025.
  • 94 funds tracked by Wall St. Rank held CureVac as of Q3 2025.

Based on Kathmere Capital Management's 13F filing for Q3 2025, filed 22 Oct 2025.